BIOVIA provides insight into druggability and intelligence on investigational drugs by providing access to one of the world’s leading collections of bioactivity data.
Understand the competitive space for biologically active molecules and develop structure-activity relationships (SARs) using one of the most authoritative and current collections of bioactivity findings for newly launched or developmental drugs. MDDR is an electronic version of the Drug Data Report publication and is jointly produced by BIOVIA and Clarivate Analytics (España) SAU.
Following criteria is a guide for MDDR products selection:
- New products in drug substance patents with biological results, preferably from companies or relevant drug discovery universities and research centers.
- New products in journal articles or conference abstracts, preferably with good preclinical data or, alternatively, other novelty such as:
- New chemical scaffold for specific biological activity
- New mechanism or mechanism with very few data available in the literature.
- New therapeutic strategy.
- New therapeutic indication.
- New code, from a company
First time Launched products are included as well.
Terms for mechanism of action indexation, when related with genes and protein targets, are based on UniProt® nomenclature.
Anticipate adverse effects based upon chemical structure and link structure with metabolism information in the largest structure-searchable compendium of compounds with reported in vivo and in vitro toxic properties. Toxicity database includes Registry of Toxic Effects of Chemical Substances (RTECS®) database that is updated quarterly. Six categories of data types are covered:
- Acute Toxicity
- Skin/Eye Irritation
- Reproductive Effects
- Other Multiple Doses
In addition, the following data sources (no further updates) are included in the Toxicity database.
- Chemical Carcinogenesis Research Information System (CCRIS), produced by the National Cancer Institute (NCI) ; Ref. 1938-2006
- Genetic Toxicity (GENE-TOX), produced by the U.S. Environmental Protection Agency (EPA) ; Ref. 1952-1987
- Genotoxicity, produced by genetic toxicity testing program of the US National Toxicology Program (NTP) ; Ref. 1983-1996
- Additional Carcinogenicity, Hepatotoxicity abstracted from scientific literature by MDL (now Dassault Systèmes BIOVIA) :
- BIOVIA Carcinogenicity; Ref. 2000
- BIOVIA Hepatotoxicity; Ref. 1999
Registry of Toxic Effects of Chemical Substances (RTECS®) was built and maintained by the National Institute of Occupational Safety and Health (NIOSH) from 1971 through January 2001. Dassault Systèmes BIOVIA continues the production of the RTECS file using the same data selection criteria and rules established by NIOSH. BIOVIA distributes quarterly updates to licensees of the RTECS database under the terms of the License and Distribution Agreement entered into on October 29, 2001 between MDL (now Dassault Systèmes BIOVIA) and the United States Public Health Service within the Department of Health and Human Services. RTECS is a comprehensive collection of basic toxicity information for over 190,000 chemical substances from pharmaceuticals to foodstuffs.